C5 and atypical hemolytic-uremic syndrome: Yoshida et al. (2022) identified specific biomarkers, such as elevated serum C5b-9 complexes and sC5b-9, that are indicative of complement activation linked to glomerular capillary thrombosis in atypical hemolytic uremic syndrome (aHUS). The study highlighted that exposure to certain drugs, such as calcineurin inhibitors, may exacerbate complement-mediated damage, contributing to glomerular capillary thrombosis.